Status:
COMPLETED
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
Lead Sponsor:
Fondazione ANT Italia ONLUS
Conditions:
Opioid Use
Constipation Drug Induced
Eligibility:
All Genders
18+ years
Brief Summary
Opioid-Induced Constipation (OIC) is often associated with a compromised quality of life of patients in palliative care (PC) setting. Among the Peripherally-Acting Mu-Opioid Receptor Antagonists, Nalo...
Eligibility Criteria
Inclusion
- cancer patients with advanced disease;
- age higher than 18 years;
- mentally competent;
- naloxegol therapy for no more than 1 week according to clinical practice;
- sign of a written informed consent.
Exclusion
- patient with pain not controlled by opioids;
- therapy with other PAMORAs;
- intestinal obstruction;
- risk of intestinal perforation.
- severe renal failure.
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04294550
Start Date
September 1 2018
End Date
March 31 2021
Last Update
February 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione ANT Italia ONLUS
Bologna, BO, Italy, 40128